STAGE IVB PROSTATE CANCER AJCC V8
Clinical trials for STAGE IVB PROSTATE CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB PROSTATE CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB PROSTATE CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a cancer drug boost radiation therapy in Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 2 trial tests whether the drug vorinostat can increase the amount of a target (PSMA) on prostate cancer cells, making them more visible to a radioactive therapy called 177Lu-PSMA-617. The study enrolls 15 men with PSMA-low metastatic castration-resistant prostate cance…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 20:48 UTC
-
Could High-Dose testosterone boost chemo against Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis phase 2 trial tests whether giving high levels of testosterone alongside chemotherapy (carboplatin or etoposide) or a targeted radioactive drug (LuPSMA) can shrink tumors in men with advanced prostate cancer that has stopped responding to hormone therapy. The study will enro…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 23, 2026 11:55 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells to damage their DNA. It is for people with prostate cancer that has spread and is no longer responding to hormone therapy. The goal is to see if this treatment can slow cance…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 22, 2026 12:07 UTC
-
New drug combo aims to tackle Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing whether adding ruxolitinib to the standard drug enzalutamide can help men with advanced prostate cancer that has spread and stopped responding to hormone therapy. Ruxolitinib blocks certain proteins that help tumors grow, while enzalutamide block…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
New combo aims to supercharge prostate cancer radiation
Disease control Recruiting nowThis study tests whether giving abemaciclib before a radioactive drug (177Lu-PSMA-617) can make prostate cancer cells more sensitive to radiation. About 30 men with advanced, treatment-resistant prostate cancer will receive abemaciclib pills for two weeks, then the radioactive th…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New combo therapy aims to boost immune attack on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests whether adding an immune-boosting vaccine (Sipuleucel-T) to a radioactive drug (Lu-PSMA) is safe and works better than the radioactive drug alone for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 30…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 18, 2026 11:49 UTC
-
Second dose of targeted radiation shows promise for tough prostate cancer
Disease control Recruiting nowThis study tests whether giving a second round of a radioactive drug called 177Lu-PSMA-617 can help men with advanced prostate cancer that no longer responds to hormone therapy. The drug targets and delivers radiation directly to cancer cells. Participants must have already had a…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
PET scans may personalize prostate cancer care after surgery
Disease control Recruiting nowThis study is for men whose prostate cancer has returned after surgery, shown by a rising PSA level. It tests whether using PET scans to see where the cancer has spread can help doctors choose the best treatment. Some participants will get standard care, while others will get str…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jun 18, 2026 11:48 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. Some participants will als…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC
-
New hope for advanced prostate cancer: PET-Guided radiation may delay progression
Disease control Recruiting nowThis study tests whether adding targeted radiation, guided by a special PET scan, to standard hormone therapy can better control prostate cancer that has spread. About 125 men with metastatic hormone-sensitive prostate cancer will be randomly assigned to receive either standard t…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 17, 2026 12:04 UTC
-
New hope for advanced prostate cancer: surgery or radiation may boost survival
Disease control Recruiting nowThis study is for men with prostate cancer that has spread to other parts of the body. It compares standard drug therapy alone versus standard drug therapy plus either surgery to remove the prostate or radiation to the prostate. The goal is to see if adding local treatment helps …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Triple therapy may extend lives in advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the chemotherapy drug docetaxel to the usual hormone therapy and apalutamide helps men with prostate cancer that has spread to other parts of the body live longer. About 1,260 men will be randomly assigned to receive either the three-drug combinati…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
Promising combo therapy aims to halt bone metastases in advanced prostate cancer
Disease control Recruiting nowThis study tests whether adding the drugs M3814 and avelumab to standard radium-223 therapy can better control advanced prostate cancer that has spread to bones. About 90 adults with castration-resistant prostate cancer will receive either radium-223 alone or with one or both add…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
Testosterone therapy shows promise for Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New hope for rare cancers: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if the combination shrinks tumors better than any single drug. About 314 adults with these rare cancers are being…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis study tests two drugs, cabozantinib and atezolizumab, in 33 men with a type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see if the combination can stop or shrink tumors. Participants must have non-measurable disease o…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 12, 2026 12:06 UTC
-
New hope for tough prostate cancer: combo chemo trial launches
Disease control Recruiting nowThis study tests whether adding carboplatin to the standard chemo drug cabazitaxel helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 528 participants will receive either cabazitaxel alone or cabazitaxel plus carboplatin. The …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Engineered immune cells take on incurable prostate cancer
Disease control Recruiting nowThis study tests a new treatment for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The treatment uses the patient's own immune cells, modified in a lab to better recognize and attack prostate cancer cells, combined with a ho…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New combo targets advanced prostate cancer in phase 2 trial
Disease control Recruiting nowThis study tests whether adding the drug talazoparib to standard hormone therapy can better control advanced prostate cancer that still responds to hormone treatment. About 70 men with cancer that has spread will receive the combination. The goal is to see if this approach lowers…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 08, 2026 13:17 UTC
-
Could fewer doses be just as effective for prostate cancer?
Disease control Recruiting nowThis study looks at whether men with advanced prostate cancer that has spread can safely stop a targeted radiation therapy after 5 cycles instead of the usual 6. The goal is to see if a shorter treatment can control the cancer just as well while reducing side effects. About 236 p…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 08, 2026 13:03 UTC
-
Freezing tumors may boost radiation pain relief for bone metastases
Symptom relief Recruiting nowThis study tests whether adding a freezing procedure called cryoablation to standard radiation therapy can better relieve pain from cancer that has spread to the bones. About 40 adults with certain cancers (like prostate, kidney, or melanoma) that have spread to the bone will be …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 22, 2026 12:08 UTC
-
Genetic roadmap may unlock smarter prostate cancer therapy
Knowledge-focused Recruiting nowThis study is for people with advanced prostate cancer that no longer responds to hormone therapy. It uses genetic testing of tumor tissue to assign patients to one of several targeted drugs, including valemetostat, carboplatin, cabazitaxel, abiraterone, enzalutamide, or a radioa…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Jun 18, 2026 11:47 UTC
-
Biopsies reveal secrets of therapy resistance in advanced prostate cancer
Knowledge-focused Recruiting nowThis study looks at why some prostate cancers become resistant to a targeted radiation treatment called 177Lu-PSMA. Researchers will take small tissue samples (biopsies) from tumors in 30 patients before and after therapy. The goal is to find genetic changes that cause resistance…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 16, 2026 12:49 UTC
-
Tailored care plans aim to bridge health literacy gap for black prostate cancer survivors
Knowledge-focused Recruiting nowThis study compares a standard survivorship care plan to one tailored for low health literacy in 150 African American men who have finished treatment for localized or limited-spread prostate cancer. The goal is to see if the tailored plan helps them better understand their follow…
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Phase: NA • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 29, 2026 14:19 UTC
-
Can DNA glitches predict prostate cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in …
Matched conditions: STAGE IVB PROSTATE CANCER AJCC V8
Sponsor: University of Washington • Aim: Knowledge-focused
Last updated May 29, 2026 14:16 UTC